288251-96-7

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
2-Isobutyl-5-nitrobenzonitrile is used as a raw material for the synthesis of various pharmaceuticals and agrochemicals. Its nitrile and nitro-containing structure makes it a valuable starting material for the production of a wide range of chemicals.
Used in Dye and Pigment Production:
2-Isobutyl-5-nitrobenzonitrile is used as a building block in the production of dyes and pigments, contributing to the development of diverse colorants for various applications.
Used in Rubber Chemical Manufacturing:
2-Isobutyl-5-nitrobenzonitrile is also utilized in the manufacturing of rubber chemicals, playing a role in enhancing the properties and performance of rubber products.
Safety Precautions:
2-Isobutyl-5-nitrobenzonitrile is a potential irritant to the skin, eyes, and respiratory system. Therefore, it should be handled with caution to minimize exposure and ensure the safety of workers and the environment.

Upstream product

• 84110-40-7 Dihydroxy-isobutyl-boran 
• 134604-07-2 2-bromo-5-nitrobenzonitrile 
• 72115-09-4 5-amino-2-bromo-benzonitrile 

Downstream Products

• 288251-97-8 5-amino-2-(2-methylpropyl)benzonitrile 
• 856167-67-4 5-bromo-2-(2-methylpropyl)benzonitrile 
• 856167-68-5 2-(2-methylpropyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile 
• 1334608-00-2 ethyl 4-(3-{2-[3-cyano-4-(2-methylpropyl)phenyl]-5-pyrimidinyl}-2-ethylphenyl)butanoate 
• 1334608-10-4 5-[5-(2-ethyl-3-formylphenyl)-2-pyrimidinyl]-2-(2-methylpropyl)benzonitrile 
• 1334608-14-8 5-(5-bromo-pyrimidin-2-yl)-2-isobutyl-benzonitrile 
• 1334608-18-2 5-(5-{2-ethyl-3-[(E)-2-(methyloxy)ethenyl]phenyl}-2-pyrimidinyl)-2-(2-methylpropyl)benzonitrile 
• 1334608-19-3 5-{5-[2-ethyl-3-(2-oxoethyl)phenyl]-2-pyrimidinyl}-2-(2-methylpropyl)benzonitrile 
• 1334608-23-9 ethyl 4-[(3-{2-[3-cyano-4-(2-methylpropyl)phenyl]-5-pyrimidinyl}-2-ethylphenyl)oxy]butanoate 
• 1334606-96-0 4-(3-{2-[3-cyano-4-(2-methylpropyl)phenyl]-5-pyrimidinyl}-2-ethylphenyl)butanoic acid 
• 1334608-27-3 methyl N-[(3-{2-[3-cyano-4-(2-methylpropyl)phenyl]-5-pyrimidinyl}-2-ethylphenyl)methyl]-N-methylglycinate 
• 1334608-26-2 methyl N-[2-(3-{2-[3-cyano-4-(2-methylpropyl)phenyl]-5-pyrimidinyl}-2-ethylphenyl)ethyl]-N-methylglycinate 
• 1334607-77-0 4-[(3-{2-[3-cyano-4-(2-methylpropyl)phenyl]-5-pyrimidinyl}-2-ethylphenyl)oxy]butanoic acid 
• 1344998-91-9 C₃₀H₃₆N₄O₂S 

Relevant academic research and scientific papers

BIARYL COMPOUND, PREPARATION METHOD AND USE THEREFOR

The present invention belongs to the technical field of chemical pharmaceuticals, and relates to a compound represented by general formula (I) or formula (II) and a preparation method thereof. The compounds are biaryl derivatives with RORγt activation activity. The biaryl derivatives disclosed in this invention can effectively activate the RORγt protein receptor, and thereby promote the differentiation of Th17 cells and increasing the production of IL-17, which can be used as an immune modulator for the treatment of various cancers or viral infection-related diseases.

PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Disclosed are pyrimidine derivatives for use as a sphingosine 1-phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or diseases mediated by S1P1 receptors, particularly multiple sclerosis.

NOVEL S1P RECEPTOR MODULATING AGENT

An object of the present invention is to provide a compound having a modulating activity at an S1P receptor which is useful for preventing and treating autoimmune diseases, allergic diseases, and the like. According to the present invention, a compound re

PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Disclosed are pyrimidine derivatives for use as sphingosine 1- phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or diseases mediated by S1P1 receptors, particularly multiple sclerosis.

COMPOUNDS AS AGONISTS OF S1P1 RECEPTORS

Compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by S1P1 receptors.